Erasca Inc Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Hagens Berman filed a securities class action against Erasca Inc. (NASDAQ: ERAS) for alleged federal securities law violations. The lawsuit represents investors who purchased stock between January 14, 2025 and April 26, 2026. Claims center on alleged misrepresentations about ERAS-0015 drug safety and intellectual property protection. Revolution Medicines accused Erasca of patent infringement and trade secret misappropriation regarding the cancer treatment. A patient death and IP disputes caused Erasca's stock to plummet 48%, eliminating $2.8 billion in market capitalization.